PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 15, 2017SHILAP Revista de lepidopterología251 citationsOpen Access

Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients

MEMikaël EbboAGA. GradosMSM. Samson

Key Points

Key points are not available for this paper at this time.

Abstract

RTX is effective for both induction therapy and treatment of relapses in IgG4-RD, but relapses are frequent after B-cell reconstitution. Maintenance therapy with systematic RTX infusions is associated with longer relapse-free survival and might represent a novel treatment strategy. Yet, the high rate of infections and the temporary effect of RTX might be hindrances to such strategy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ebbo et al. (2017) studied this question.

synapsesocial.com/papers/69df2ab458b92af24d7a114ahttps://doi.org/10.1371/journal.pone.0183844
Ask AI
Helpful
Bookmark
Share
View Full Paper